SCHEMBL5557487

SCHEMBL5557487

COC(=O)c1cccc(-c2cnccn2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.60
CDK8 P49336 1/20 0.58
ABL1 P00519 2/20 0.57
BCR P11274 1/20 0.57
SRC P12931 1/20 0.57
ALDH1A1 P00352 1/20 0.57
NEK1 Q96PY6 4/20 0.56
GABRG2 P18507 1/20 0.56
GABRB3 P28472 1/20 0.56
GABRA5 P31644 1/20 0.56
GABRA3 P34903 1/20 0.56
PIM2 Q9P1W9 1/20 0.53
CYP19A1 P11511 1/20 0.53
CYP11B1 P15538 1/20 0.53
CYP11B2 P19099 1/20 0.53
KDM4E B2RXH2 1/20 0.51
KDM6B O15054 1/20 0.51
KDM5C P41229 1/20 0.51
KDM4C Q9H3R0 1/20 0.51
KDM2A Q9Y2K7 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL475718 0.88 ALDH1A1 (0.51) RAB9ACDK8ABL1BCRSRC
SCHEMBL30109243 0.84 ALDH1A1 (0.56) RAB9AALDH1A1CYP19A1CYP11B1CYP11B2
SCHEMBL14886472 0.84 ALDH1A1 (0.56) RAB9AALDH1A1CYP19A1CYP11B1CYP11B2
SCHEMBL1399775 0.83 CYP19A1 (0.74) RAB9ACDK8ABL1BCRSRC
SCHEMBL6468727 0.82 KDM4E (0.52) RAB9ACDK8ABL1BCRSRC
SCHEMBL5562975 0.81 GRM5 (0.64) CDK8ABL1BCRSRCNEK1
SCHEMBL4775152 0.81 KMO (0.68) ABL1BCRALDH1A1PIM2KDM4E
SCHEMBL5558179 0.81 CDK8 (0.56) RAB9ACDK8ABL1BCRSRC
SCHEMBL3713394 0.81 ABL1 (0.66) RAB9AABL1BCRSRCALDH1A1
SCHEMBL30151105 0.81 ABL1 (0.66) RAB9AABL1BCRSRCALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474416-B1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS HOFFMANN LA ROCHE (CH) 2007-09-26 EP disclosed
US-6949542-B2 Dihydro-benzo[b][1,4]diazepin-2-one derivatives HOFFMAN-LA ROCHE INC. (US) 2005-09-27 US disclosed
EP-1474416-A1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG (CH) 2003-09-04 US disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives CYP1B1, GRIN2B, CYP4B1 RAB9A 2759/4885CDK8 2388/4885ABL1 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.